Evidence map›Paper›PMID 32597823›Full record

ReviewRestorative neurology and neuroscience2020

AhR and IDO1 in pathogenesis of Covid-19 and the "Systemic AhR Activation Syndrome:" a translational review and therapeutic perspectives.

Waldemar A Turski, Artur Wnorowski, Gabrielle N Turski, Christopher A Turski, Lechoslaw Turski

Open access · bronzeAbstract readReview
In one paragraph

Review in Restorative neurology and neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Classification and regulatory interactions of key transcription factors in COVID-19.Frontiers in cellular and infection microbiology · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. When the clock ticks wrong with COVID-19.Clinical and translational medicine · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Waldemar A TurskiDepartment of Experimental and Clinical Pharmacology, Medical University, Lublin, Poland.
Artur WnorowskiDepartment of Biopharmacy, Faculty of Pharmacy, Medical University, Lublin, Poland.
Gabrielle N TurskiDepartment of Ophthalmology, University of Bonn, Bonn, Germany.
Christopher A TurskiDepartment of Ophthalmology, University of Bonn, Bonn, Germany.
Lechoslaw TurskiGerman Center for Neurodegenerative Diseases, Bonn, Germany.
Medical University of Lublin · PLUniversity of Bonn · DEGerman Center for Neurodegenerative Diseases · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Covid-19 is the acute illness caused by SARS-CoV-2 with initial clinical symptoms such as cough, fever, malaise, headache, and anosmia. After entry into cells, corona viruses (CoV) activate aryl hydrocarbon receptors (AhRs) by an indoleamine 2,3-dioxygenase (IDO1)-independent mechanism, bypassing the IDO1-kynurenine-AhR pathway. The IDO1-kynurenine-AhR signaling pathway is used by multiple viral, microbial and parasitic pathogens to activate AhRs and to establish infections. AhRs enhance their own activity through an IDO1-AhR-IDO1 positive feedback loop prolonging activation induced by pathogens. Direct activation of AhRs by CoV induces immediate and simultaneous up-regulation of diverse AhR-dependent downstream effectors, and this, in turn, results in a "Systemic AhR Activation Syndrome" (SAAS) consisting of inflammation, thromboembolism, and fibrosis, culminating in multiple organ injuries, and death. Activation of AhRs by CoV may lead to diverse sets of phenotypic disease pictures depending on time after infection, overall state of health, hormonal balance, age, gender, comorbidities, but also diet and environmental factors modulating AhRs. We hypothesize that elimination of factors known to up-regulate AhRs, or implementation of measures known to down-regulate AhRs, should decrease severity of infection. Although therapies selectively down-regulating both AhR and IDO1 are currently lacking, medications in clinical use such as dexamethasone may down-regulate both AhR and IDO1 genes, as calcitriol/vitamin D3 may down-regulate the AhR gene, and tocopherol/vitamin E may down-regulate the IDO1 gene. Supplementation of calcitriol should therefore be subjected to epidemiological studies and tested in prospective trials for prevention of CoV infections, as should tocopherol, whereas dexamethasone could be tried in interventional trials. Because lack of physical exercise activates AhRs via the IDO1-kynurenine-AhR signaling pathway increasing risk of infection, physical exercise should be encouraged during quarantines and stay-at-home orders during pandemic outbreaks. Understanding which factors affect gene expression of both AhR and IDO1 may help in designing therapies to prevent and treat humans suffering from Covid-19.

Indexed as

PandemicsAir PollutantsBetacoronavirusCalcitriolCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDexamethasoneExerciseFeedback, PhysiologicalFemaleFibrosisGene Expression RegulationHumansIndoleamine-Pyrrole 2,3,-DioxygenaseInflammationAir PollutantsCalcitriolDexamethasoneIDO1 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenineReceptors, Aryl HydrocarbonTocopherolsaryl hydrocarbon receptorbrain injuryCorona virusCovid-19dexamethasonefibrosisindoleamine 2,3-dioxygenaseinflammationmultiple organ injuryphysical exerciserespiratory failureSARS-CoV-2systemic AhR activation syndrome (SAAS)thromboembolismvitamin Dvitamin E

Identifiers

PMID32597823
PMCPMC7592680
OpenAlexW3037930853

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.